These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25370296)

  • 21. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
    Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between Benton Visual Retention Test Scores and PET Imaging in Elderly Adults.
    Abe M; Kimura N; Sasaki Y; Eguchi A; Matsubara E
    Curr Alzheimer Res; 2021; 18(11):900-907. PubMed ID: 34875990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Connectivity analysis of normal and mild cognitive impairment patients based on FDG and PiB-PET images.
    Son SJ; Kim J; Seo J; Lee JM; Park H;
    Neurosci Res; 2015 Sep; 98():50-8. PubMed ID: 25896866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].
    Cao Q; Jiang K; Liu Y; Zhang M; Xiao S; Zuo C; Huang H
    Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1613-6. PubMed ID: 12667368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early detection of Alzheimer's disease using PiB and FDG PET.
    Cohen AD; Klunk WE
    Neurobiol Dis; 2014 Dec; 72 Pt A():117-22. PubMed ID: 24825318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
    Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
    J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Brain Amyloid Deposition and Cortical Glucose Metabolism Between Clinic- and Community-Based Cohort.
    Yabuuchi K; Kimura N; Masuda T; Matsubara E
    J Alzheimers Dis; 2023; 95(1):299-306. PubMed ID: 37483008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
    Devanand DP; Mikhno A; Pelton GH; Cuasay K; Pradhaban G; Dileep Kumar JS; Upton N; Lai R; Gunn RN; Libri V; Liu X; van Heertum R; Mann JJ; Parsey RV
    J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):185-98. PubMed ID: 20430977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
    Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
    Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
    Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional glucose metabolism due to the presence of cerebral amyloidopathy in older adults with depression and mild cognitive impairment.
    Youn H; Lee ES; Lee S; Suh S; Jeong HG; Eo JS
    J Affect Disord; 2018 Oct; 239():30-36. PubMed ID: 29991443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.
    Pagani M; De Carli F; Morbelli S; Öberg J; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BN; Ossenkoppele R; Didic M; Guedj E; Brugnolo A; Picco A; Arnaldi D; Ferrara M; Buschiazzo A; Sambuceti G; Nobili F
    Neuroimage Clin; 2015; 7():34-42. PubMed ID: 25610765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
    Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
    Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
    Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.